30/04/2021
PROFARMA HAS ONCE AGAIN RATED ESTEVE’S RESEARCH AND INNOVATION ACTIVITY AS "EXCELLENT"
ESTEVE has been ranked as ''Excellent'' by the Profarma Plan due to its activity in the fields of research, innovation and production
As this is the highest possible rating, the company therefore continues in the plans Group A, which includes pharmaceutical companies that lead the way in R+D+i.
The Profarma Plan, also known as the Plan for the Promotion of Scientific Research and Technological Development and Innovation (R&D&I) in the Pharmaceutical Industry, is a joint program of the Ministry of Economy, Industry and Competitiveness and the Ministry of Health, Social Services and Equality.
This plan ranks companies as ''Acceptable'', ''Good'', ''Very Good'' and ''Excellent'', and its objective is to increase the competitiveness of the pharmaceutical sector by promoting research, development and innovation, modernizing the industry, and investing, for example, in new industrial plants and in the latest technology.
ESTEVE has developed several proprietary and collaborative programs, primarily in the field of neurosciences, which are currently at different stages of research and development.
